August 26th 2025
Read the full, exclusive transcript from the inaugural "Brain Trust: Conversations in Clinical Psychopharmacology" video with Joseph F. Goldberg, MD, and Marlene Freeman, MD.
Integrative Management of Schizophrenia
May 13th 2014Select natural products have been evaluated as adjunctive agents that may be combined with conventional antipsychotics, with promising preliminary findings. Music therapy, meditation, and mindfulness training may improve quality of life for individuals with schizophrenia. Details here.
Read More
Course and Treatment Outcomes of ADHD
May 12th 2014What factors are involved in parents’ decision to begin medication treatment for a child with ADHD? An overview of studies that provide clinically relevant information related to the course and treatment outcomes of ADHD in children and adolescents.
Read More
Treatment-Resistant Depression: An Alternative Approach to Management
May 1st 2014In this podcast, B. Andrew Farah, MD, looks at shortcomings of current therapy that make treatment-resistant depression so common, offers insights into the genetic underpinnings of TRD, and focuses on a new treatment paradigm.
Read More
To Supplement or Not to Supplement: That Is the Bipolar Depression Question
March 13th 2014With the multitude of nutritional products available to patients via the Internet and health-food stores, psychiatrists need to be prepared to respond to questions from patients about the value of these supplements.
Read More
Recurrent Brief Mixed Depression
December 31st 2013This case study of a 21-year-old woman-referred by a relative because of long-standing severe interpersonal, academic, and occupational impairment-illustrates the importance of screening patients with brief episodes of depression for mixed features.
Read More
Benzodiazepines vs Antidepressants for Anxiety Disorders
December 19th 2013A recent systematic review and meta-analysis that compared benzodiazepines with antidepressants for anxiety disorders has triggered a debate among clinicians about first-line treatments, efficacy for specific disorders, and adverse effects.
Read More
Risperdal Maker Pays High Price to Resolve Criminal and Civil Investigations
November 8th 2013Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by FDA and payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider.
Read More
“Switching” of Mood From Depression to Mania With Antidepressants
Mood switching is not uncommon and it is much more prevalent in depressed juveniles than in depressed adults, and there is a large apparent excess of antidepressant-associated switching over reported spontaneous diagnostic changes to bipolar disorder. Details here.
Read More
A Risk Stratification Approach to Alcohol Detoxification
November 5th 2013The challenges of identifying patients at risk for alcohol withdrawal have been found to be mitigated by the development of a Risk Stratification Questionnaire, now being adopted by the VA regionally throughout New England. More in this video.
Read More